283 related articles for article (PubMed ID: 34535993)
21. Reply to: RAAS inhibitors in COVID-19: Not all are created equal!
Gonçalves J; Santos CD; Fresco P; Fernandez-Llimos F
Rev Port Cardiol; 2023 Sep; 42(9):817-818. PubMed ID: 37356667
[No Abstract] [Full Text] [Related]
22. Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.
Sriram K; Insel PA
Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L37-L38. PubMed ID: 33496632
[No Abstract] [Full Text] [Related]
23. Potential Roles of the Renin-Angiotensin System in the Pathogenesis and Treatment of COVID-19.
Lu L; Liu X; Jin R; Guan R; Lin R; Qu Z
Biomed Res Int; 2020; 2020():7520746. PubMed ID: 33204713
[TBL] [Abstract][Full Text] [Related]
24. ACE2: from protection of liver disease to propagation of COVID-19.
Warner FJ; Rajapaksha H; Shackel N; Herath CB
Clin Sci (Lond); 2020 Dec; 134(23):3137-3158. PubMed ID: 33284956
[TBL] [Abstract][Full Text] [Related]
25. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
[TBL] [Abstract][Full Text] [Related]
26. COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial.
Mancia G
Cardiovasc Res; 2020 Dec; 116(14):e198-e199. PubMed ID: 33245754
[No Abstract] [Full Text] [Related]
27. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
28. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
Baral R; White M; Vassiliou VS
Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
[TBL] [Abstract][Full Text] [Related]
29. [Cardiac Involvement in COVID-19].
Sugraliyev AB
Kardiologiia; 2021 May; 61(4):15-23. PubMed ID: 33998404
[TBL] [Abstract][Full Text] [Related]
30. COVID-19 and renin-angiotensin system modulators: what do we know so far?
de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19.
Haslbauer JD; Stalder A; Zinner C; Bassetti S; Mertz KD; Went P; Matter M; Tzankov A
Pathobiology; 2022; 89(3):166-177. PubMed ID: 34915500
[TBL] [Abstract][Full Text] [Related]
32. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19.
Rieder M; Wirth L; Pollmeier L; Jeserich M; Goller I; Baldus N; Schmid B; Busch HJ; Hofmann M; Kern W; Bode C; Duerschmied D; Lother A
Am J Hypertens; 2021 Apr; 34(3):278-281. PubMed ID: 33043967
[TBL] [Abstract][Full Text] [Related]
33. Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19.
Loader J; Lampa E; Gustafsson S; Cars T; Sundström J
J Am Heart Assoc; 2021 Aug; 10(15):e021154. PubMed ID: 34320843
[TBL] [Abstract][Full Text] [Related]
34. Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
Henry RA
CMAJ; 2020 Jun; 192(26):E728. PubMed ID: 32601254
[No Abstract] [Full Text] [Related]
35. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Cappuccio FP; Siani A
Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
[TBL] [Abstract][Full Text] [Related]
36. Influence of blood pressure control and application of renin-angiotensin-aldosterone system inhibitors on the outcomes in COVID-19 patients with hypertension.
Chen R; Yang J; Gao X; Ding X; Yang Y; Shen Y; He C; Xiang H; Ke J; Yuan F; Cheng R; Lv H; Li P; Zhang L; Liu C; Tan H; Huang L
J Clin Hypertens (Greenwich); 2020 Nov; 22(11):1974-1983. PubMed ID: 33006442
[TBL] [Abstract][Full Text] [Related]
37. Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
Volpe M; Battistoni A
Int J Cardiol; 2020 Dec; 321():150-154. PubMed ID: 32738257
[TBL] [Abstract][Full Text] [Related]
38. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
39. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of the renin-angiotensin-aldosterone system and COVID-19 in critically ill elderly patients.
Jung C; Bruno RR; Wernly B; Joannidis M; Oeyen S; Zafeiridis T; Marsh B; Andersen FH; Moreno R; Fernandes AM; Artigas A; Pinto BB; Schefold J; Wolff G; Kelm M; De Lange DW; Guidet B; Flaatten H; Fjølner J;
Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):76-77. PubMed ID: 32645153
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
